Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than two years of age, all adults 65 years or older, and for people 2-64 years old with certain medical conditions like Chronic lung disease, including asthma if treated with prolonged high-dose oral corticosteroid therapy. The CDC recommends pneumococcal polysaccharide vaccine for all adults 65 years or older, people 2-64 years old with certain medical conditions, and adults 19-64 years old who smoke cigarettes.
Global pneumococcal vaccines market size was valued at US$ 6,615.94 Million in 2022 and is expected to witness a CAGR of 4.4% over the forecast period (2022 – 2030).
Figure 1.Global Pneumococcal Vaccines Market Share (%), by Vaccine Type, 2022
Increasing partnership of manufacturers with various governments of countries is expected to drive growth of the pneumococcal vaccines market
Various manufacturers for vaccines are engaged in new projects, targeting diseases with no existing vaccine for various age groups, to meet the needs of affected people in emerging economics. This would help the companies like GlaxoSmithKline plc. to sustain in their vaccine business for long-term.
For instance, according to data published by the UNICEF (United Nations International Children's Emergency Fund) Supply Division in July 2020, more than 80% of the countries eligible to access Pneumococcal Conjugate Vaccine using the AMC (Advance market commitment) have introduced the vaccine into their national immunization programs.
Moreover, in June 2021, the government of Indonesia with support from Gavi, the Vaccine Alliance, UNICEF, the Bill and Melinda Gates Foundation, and other partners introduced pneumococcal conjugate vaccine (PCV) across the country to immunize around 4.5 million children against pneumococcus bacteria. Furthermore, in October 2021, the Government of India launched nationwide expansion of Pneumococcal Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP). Increasing initiatives by various countries to introduce such vaccines in collaboration with funding programs are expected to result the growth in the overall revenue of the pneumococcal vaccines market during the forecast period.
|Base Year:||2021||Market Size in 2022:||US$ 6,615.94 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.4%||2030 Value Projection:||US$ 9,360.79 Mn|
Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
|Restraints & Challenges:||
Figure 2. Pneumococcal Vaccines Market Share (%), by Region, 2022
Demand for pneumococcal vaccines in the North America is driven due to strong economy and rising trends of home nursing facilities.
Increasing research and development activities by key players in market for developing global pneumococcal vaccines market is expected to drive market growth over the forecast period. For instance, in June 2020, UNICEF and Serum Institute of India (SII), an India-based biotechnology company, entered into a new supply agreement to make pneumococcal conjugate vaccine (PCV) available at US$ 2.00 per dose, which is a 43% reduction from the Gavi price at the start of the Advance Market Commitment in low income countries such as Pakistan, Nigeria, Uganda, Kenya.
Global Pneumococcal Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals. According to official data given by World Health Organization and UNICEF, around 23 million children lost out on basic immunizations through routine immunization programme in 2020 – 3.7 million more than in 2019 – according to an article published by the United Nations Children's Fund (UNICEF) on July 15, 2021. The majority of countries saw decline in childhood vaccination rates in 2020, according to the most recent set of comprehensive global childhood immunization numbers, which are the first official figures to include global service disruptions due to COVID-19 pandemic.
However, according to vaccine update published by public health England (PHE) in May 2021, during April and May 2020, PHE conducted an online survey and interviews to find guard out parents’ and experiences of accessing routine childhood vaccinations during the first wave of the coronavirus (COVID-19) pandemic and the first national lockdown. During the early phase of the pandemic, vaccination counts were 20% lower than the same period in 2019 in Europe region, before recovering in mid-April. The study aimed to identify barriers to accessing routine childhood vaccination during the early phase of the pandemic in Europe.
Global Pneumococcal Vaccines Market: Key Developments
Pneumococcal Vaccines Market Restraints
The higher prices of various pneumococcal vaccines including, PCV13 is a concern for various funding agencies and players in both public and private sectors.
During 2013-2014, the U.S. government bought the PCV13 vaccine from Pfizer at around US$ 284.5 for a single child’s vaccination.
Moreover, in various countries such as India, PCV13 and PCV10 are priced at around US$ 59/dose and US$ 28/dose respectively, with three doses needed for full vaccination, in the private market (reported by Medecins Sans Frontieres (MSF), a humanitarian organization). In August 2017, Indian Patent Office granted patent for Pfizer’s Prevenar13 pneumococcal vaccine, which would extend upto year 2026. This same patent was revoked in 2014 by the European Patent Office (EPO), which was considered as a far more patent-friendly body, as opposed to India, which has been more reluctant in patenting any pharmaceutical.
Key players operating in the global pneumococcal vaccines market include Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
Pneumococcal disease is a common and often mild infection that includes conditions such as middle ear infection, a blood infection, pneumonia, and bacterial meningitis. However, the disease can sometimes result in severe and fatal health problems. Pneumococcal vaccines offer protection against streptococcus pneumonia, which is a causative agent. The vaccine is available in two types as conjugate vaccine and polysaccharide vaccine. Pneumococcal vaccines are administered through intramuscular route. Conjugate vaccines are administered to infants, while polysaccharide vaccines are effective in healthy adults.
Pharmaceutical companies are reluctant to invest in production of new vaccines, owing to very less returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange of continuous supply of vaccines from vendors at sustainable prices for long term.
For instance, in April 2018, Merck & Co., Inc., which is also known as MSD outside of the U.S. and Canada, started two Phase 3 studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The company initiated follow-up programmes with the vaccine, looking at different adult age groups, neonatal immunization, and childhood immunization. This vaccine, when launched, would compete with Pfizer’s established pneumococcal vaccine known as Prevnar-13.
Moreover, in September 2018, Pfizer received Breakthrough Therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077 and got a competitive advantage with Merck & Co to bring a new-generation pneumococcal vaccine to the U.S. market. This proposed vaccine candidate is indicated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older. The U.S.FDA also granted fast-track status for PF-06482077 in 2017.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.